An overview on 5alpha-reductase inhibitors.

Area of Science:

• Urology
• Pharmacology
• Androgen Biology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS) due to prostate gland enlargement.
• Prevalence increases with age, affecting approximately 70% of men by 70 years old.
• Elevated dihydrotestosterone (DHT) levels, driven by 5alpha-reductase activity, are central to BPH pathogenesis.

Purpose of the Study:

• To review all categories of 5alpha-reductase inhibitors for BPH treatment.
• To discuss steroidal and non-steroidal inhibitors targeting testosterone to DHT conversion.

Main Methods:

• Review of existing literature on 5alpha-reductase inhibitors.
• Analysis of steroidal inhibitors (Finasteride, Dutasteride) and non-steroidal compounds.
• Examination of their mechanisms of action and efficacy in reducing DHT and prostate size.

Main Results:

• Finasteride, a steroidal inhibitor, reduces prostatic DHT by 70-90% and prostate size.
• Dutasteride, a dual inhibitor of 5alpha-reductase isozymes, reduces DHT levels by over 90%.
• Development of various non-steroidal 5alpha-reductase inhibitors has also been explored.

Conclusions:

• 5alpha-reductase inhibitors are a logical therapeutic strategy for BPH.
• Both steroidal and non-steroidal inhibitors offer effective means to suppress androgen action in the prostate.
• Continued research into novel inhibitors aims to improve BPH management.